https://orcid.org/0000-0002-7195-1845
References
- NIH Consensus Development Panel on Osteoporosis Preventation, Diagnosis, and Therapy. Osteoporosis preventation, diagnosis, and therapy. JAMA. 2001;285(6):785–795.
- Czerwinski E, Badurski JE, Marcinowska-Suchowierska E, et al. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil. 2007;9(4):337–356.
- Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complications in patients with β thalassemia major. Bone. 2011;48(3):425–432.
- Toumba M, Skordis N. Osteoporosis syndrome in thalassaemia major: an overview. J Osteoporos. 2010;2010:537673.
- Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–323.
- Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–319.
- Morabito N, Gaudio A, Lasco A, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res. 2004;19(5):722–927.
- Brinker MR, Thomas KA, Meyers SJ, et al. Bone mineral density of the lumbar spine and proximal femur is decreased in children with sickle cell anemia. Am J Orthop. 1998;27(1):43–49.
- Working Party of the General Haematology Task Force of the British Committee for Standarts in Haematology. The laboratory diagnosis of haemoglobinopathies. Br J Haematol. 1998;101(4):783–792.
- Greep N, Anderson AL, Gallagher JC. Thalassemia minor: a risk factor for osteoporosis?. Bone Min. 1992;16(1):63–72.
- Kalef-Ezra J, Challa A, Chaliasos N, et al. Bone minerals in β-thalassemia minor. Bone. 1995;16(6):651–655.
- Voskaridou E, Stoupa E, Antoniadou L, et al. Osteoporosis and osteosclerosis in sickle cell/β-thalassemia: the role of the RANKL/osteoprotegerin axis. Haematologica. 2006;91(6):813–816.